|
KMID : 0941820130230030223
|
|
Korean Journal of Clinical Pharmacy
2013 Volume.23 No. 3 p.223 ~ p.231
|
|
|
Rituximab Infusion-related Adverse Events and Risk Factors
|
|
Lee Eun-Jung
Kim Young-Ju
Rhie Sandy Jeong
|
|
|
Abstract
|
|
|
Objective: This study aimed to identify the status and risk factors of rituximab infusion-related adverse events (ADE) in rituximab-naive patients with cancer diseases.
Method: A retrospective analysis using electronic medical records review was conducted. Inclusions were patients with a diagnosis of cancer disease with the initiation of rituximabincluded treatment who were naive to rituximab during January 2011 to March 2013 at National Cancer Center (NCC)
in Korea.
Result: Total 110 patients, 582 cases of rituximab administrations, were reported in the study. About 57.2% of patients were 51-70 years old and evenly distributed between two genders and 72.7% were BMI less than 25 kg/m2.All of study patients were diagnosed with non-Hodgkin lymphoma. Fifty patients (45.4%) and 54 cases (9.3%) were experienced rituximab infusion-related AEs even with conservative administration protocol at NCC. The most frequently occurring AEs were shivering followed by rash and itching. In single variant analysis, we found that the early stage of NHL, low exposure to rituximab administrations, high white blood cell counts, high lymphocyte counts, high absolute neutrophil count and low lactate dehydrogenase were associated with infusion-related AEs (p<0.05). The early stage of disease, high lymphocyte counts, low exposure to rituximab administrations were also related significantly with AEs in multiple variants analysis (p<0.05).
Conclusion: Rituximab infusion-related AEs for patients who were naive to rituximab were still a concern with conservative administration protocol. The adverse drug reactions were significantly associated with early stage of NHL, higher lymphocyte counts and low exposure to rituximab administrations. The factors need to be considered with close monitoring to prevent rituximab infusion-related AE.
|
|
|
KEYWORD
|
|
|
Monoclonal antibodies, Rituximab, Adverse reactions, Risk factors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|